Skip to main content
. 2009 Aug 19;2009:460764. doi: 10.1155/2009/460764

Table 2.

The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [19–23].

TZDs versus placebo Pioglitazone Rosiglitazone
Total cholesterol Neutral Raised
LDL Neutral Raised
HDL Raised Raised
Triglycerides Reduced Neutral
HbA1c ↓ 1–1.5% ↓ 1–1.5%